Laboratory-Treated T Cells and Ipilimumab in Treating Patients With Metastatic Melanoma

Trial Profile

Laboratory-Treated T Cells and Ipilimumab in Treating Patients With Metastatic Melanoma

Completed
Phase of Trial: Phase I/II

Latest Information Update: 20 Apr 2017

At a glance

  • Drugs Ipilimumab (Primary) ; Aldesleukin; Cyclophosphamide; T cell replacement therapy
  • Indications Malignant melanoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 06 Jun 2016 Results published in the Journal of Clinical Oncology
    • 26 Aug 2013 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top